Effects of VLDL and Remnant Particles on PlateletsOlufadi R.a · Byrne C.D.b
Departments of aChemical Pathology (MP 6) and bEndocrinology and Metabolism (CF 96), Southampton General Hospital, Southampton, UK
Prof. Christopher D. Byrne
Endocrinology and Metabolism, Level F, Centre Block (MP113-Room CF 96)
Southampton General Hospital, Southampton SO16 6YD (UK)
Tel. +44 23 8079 8818, Fax +44 23 8079 4945
Do you have an account?
There is a considerable body of evidence supporting an association between hypertriglyceridaemia, a hypercoagulable state and atherothrombosis. A disorder of triglyceride metabolism is a key feature of the metabolic syndrome that increases risk of both ischaemic heart disease and type 2 diabetes approximately 3-fold. An increasing prevalence of obesity and metabolic syndrome is likely to contribute markedly to the prevalent ischaemic heart in the foreseeable future, and therefore it is crucial to understand mechanisms linking hypertriglyceridaemia and a hypercoagulable state. Activation of platelets and the coagulation cascade are intertwined. VLDL and remnant lipoprotein concentrations are often increased with the metabolic syndrome. These lipoproteins have the capacity to activate platelets and the coagulation pathway, and to support the assembly of the prothrombinase complex. VLDL also upregulates expression of the plasminogen activator inhibitor-1 gene and plasminogen activator inhibitor-1 antigen and activity, a process accompanied by platelet aggregation and clot formation. The surface membrane of activated platelets also supports the assembly and activity of the prothrombinase complex, resulting in further thrombin generation and amplification of the coagulation cascade. Fibrinolysis is also less efficient when thrombin is generated. Thrombin induces thrombin activatable fibrinolysis inhibitor. Thrombin activatable fibrinolysis inhibitor is a carboxypeptidase that cleaves the carboxylic lysine residues on fibrin, thereby abolishing the critical binding site for tPA-plasminogen decreasing plasmin formation. Thus the evidence is supportive of dysregulated coagulation, and impaired fibrinolysis with a predisposition to atherothrombosis, in conditions such as the metabolic syndrome, in which there are increased concentrations of VLDL and remnant lipoproteins. The purpose of this review is to describe the current evidence supporting a procoagulant state induced by VLDL and remnant lipoproteins. The role of these lipoprotein classes in (1) platelet activation; (2) the intrinsic coagulation cascade, and (3) clot formation and fibrinolysis is discussed.
© 2006 S. Karger AG, Basel
- Ford ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:309–314.
- Isomaa B, Almgre P, Tuomi T, Forsen B, Lahti K, Nissen M: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689.
- Sobel BE, Schneider DJ: Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin 2004;22:511–526.
- Yamazaki M, Uchiyama S, Xiong Y, Nakano T, Nakamura T, Iwata M: Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb Res 2005;115:211–218.
- Surya II, Akkerman JWN: The influence of lipoproteins on blood platelets. Am Heart J 1993;125:272–275.
- Aviram M, Brook JG: Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis 1983;13:344–350.
- Saniabadi AR, Umemura K, Shimoyama M, Adachi M, Nakano M, Nakashima M: Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoprotein. Thromb Haemost 1997;77:996–1001.
- Saniabadi AR, Umemura K, Suzuki Y, Kondo K, Ikeda Y, Adachi M: Adenosine 5′ diphosphate as a factor in platelet aggregation induced by human plasma remnant like lipoproteins. Life Sci 1998;63:1065–1074.
- Pedreno J, Hurt-Camejo E, Wiklund O, Badimon L, Masana L: Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very low density lipoprotein. Metabolism 2000;49:942–949.
- Englyst NA, Taube JM, Aitman TJ, Baglin TP, Bryne CD: A novel role for CD36 in VLDL- enhanced platelet activation. Diabetes 2003;52:1248–1255.
- Kohler HP: Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002;132:241–252.
Hodis H, Mack WJ, Krauss RM, Alaupovic P: Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Clin Cardiol 1999;22(suppl):II15–II20.
- Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943–949.
- Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213–219.
- Juhan-Vague I, Alessi MC, Vague P: Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin dependent diabetes mellitus. Ann Med 1996;28:371–380.
- Klein S, Spannagl M, Engelmann B: Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very low density lipoproteins. Arterioscler Thromb Vasc Biol 2001;21:1695–1700.
- Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP: Risk of coronary heart disease and activation of factor XII in middle aged men. Arterioscler Thromb Vasc Biol 1997;17:2103–2106.
- Kohler HP, Carter AM, Stickland MH, Grant PJ: Levels of activated factor XII in survivors of myocardial infarction: association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998;79:14–18.
- Ishii K, Oguchi S, Murata M, Mitsuyoshi Y, Takeshita E, Ito D, Tanahashi N, Fukuuchi Y, Oosumi K, Matsumoto K, Kitajima M, Yamamoto M, Watanabe G, Ikeda Y, Watanabe K: Activated factor XII levels are dependent on factor XII 46 C/T genotype and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects. Blood Coagul Fibrinolysis 2000;11:277–284.
- Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ: Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary artery disease in men. Circulation 2000;102:2058–2062.
- Mitropoulos KA, Miller GJ, Watts GF, Durrington PN: Lipolysis of triglyceride-rich lipoprotein activates coagulation factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis 1992;95:119–125.
- Deguchi H, Fernandez JA, Hackeng TM, BanKa CL, Griffin JH: Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000;97:1743–1748.
Skipski VP: Lipid composition of lipoproteins in normal and diseased states; in Nelson GJ (ed): Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York, NY, Wiley Interscience, 1972, pp 471–583.
- Rota S, McWilliam NA, Baglin TP, Bryne CD: Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 1998;91:508–515.
- Moyer PM, Tracy RP, Tracy PB, Veer CV, Sparks CE, Mann KG: Plasma lipoprotein support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998;18:458–465.
Bradley WA, Gianturco SH: Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost 1998;14:253–257.
- Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP: The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335–343.
- Mavri A, Alessi MC, Juhan-Vague I: Hypofibrinolysis in the insulin resistance syndrome: Implication in cardiovascular diseases. J Intern Med 2004;255:448–456.
- Kohler HP, Grant PJ: Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792–1801.
- Eriksson P, Nilsson L, Karpe F, Hamsten A: Very-low density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18:20–26.
- Lyon CJ, Hseuh WA: Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003;115:S62–S68.
- Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M: The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998;136:109–114.
- Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. A potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213–2221.
- Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore G, Pellegrini G, Vitacolonna E, Capani F, Consoli A: Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001;21:1378–1382.
- Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I: Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994;72:44–53.